That can't be supported, given that the two months in question is only a median from a review (of FDA drug approvals for solid tumors from '02 to '14). https://

That can't be supported, given that the two months in question is only a median from a review (of FDA drug approvals for solid tumors from '02 to '14). https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/1891387 https://jamanetwork.com/journals/jamaotolaryngology/article-... You'd need to explore the data behind the individual approvals to comment on statistical validity. But without going that deep, you can be assured that the FDA is generally pretty conservative, and employs very robust statistical methodology.